For comparison, Forxiga (known as Farxiga in the US) was shown in the DAPA-CKD to cut by 39% the risk of kidney disease progression, or death from kidney or cardiovascular causes. The new approval ...

Forxiga was approved for CKD on the strength of the DAPA-CKD trial, which found that adding the drug to standard care in people with CKD reduced the risk of worsening renal function, the onset of ...

Prevalence of cognitive impairment and dementia in people with kidney disease is disproportionately high, and improved detection is needed. Implementing routine screening for dementia in people ...